Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/05/042935
CTRI/2022/05/042935
Not yet recruiting
未知

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of ViphyllinTM on Brain Health and Cognitive function in Healthy Subjects.

Vidya Herbs Pvt Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Vidya Herbs Pvt Ltd
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects with a MMSE Score \>\= 23
  • •2\. Diabetes, hypertension and other medical condition patients should be on stable medication for last 3 months
  • •3\. Should not be an any medication for cognition and other neurological disorders
  • •4\. Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening
  • •5\. Non\-smokers
  • •6\. Able to communicate verbally, able to write and speak English and comfortable with using computer
  • •7\. Must be willing and able to give informed consent and comply with the study procedures.

Exclusion Criteria

  • •1\. Subjects with history of
  • •\-Respiratory bacterial or viral infection (including COVID\-19\) in the past 2 weeks
  • •\- Psychiatric disorders
  • •\- Severe neurological diseases or seizures
  • •\- Uncontrolled / serious medical illness including diabetes, liver disease, hypertension
  • •\- Cardiac Disease/Neurological Problems/
  • •\- Auto\-immune disease (rheumatoid arthritis, lupus, type 1 diabetes)
  • •\-Gastrointestinal tract bleeding / peptic ulcer disease
  • •2\. Subjects who maybe allergic to any of the natural constituents of the Investigational Product.
  • •3\. Known HIV or Hepatitis B positive or any other immuno\-compromised state

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 15.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-005109-56-GBsanofi-aventis Recherche & Développement802
Active, not recruiting
Phase 1
A study of Baricitinib in patients with LupusSystemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2017-005026-37-GREli Lilly and Company821
Active, not recruiting
Phase 1
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
EUCTR2011-005698-21-HRsanofi-aventis Recherche & Développement18,924
Active, not recruiting
Phase 1
A study in LupusPatients with Systemic Lupus Erythematosus (SLE)MedDRA version: 18.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2015-004404-35-ESilly S.A.300
Active, not recruiting
Phase 1
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic ArthropathyHemophilic ArthropathyTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2020-003602-31-PLTremeau Pharmaceuticals, Inc.160